Join to View Full Profile
2330 Shawnee Mission PkwySte 210Westwood, KS 66205
Phone+1 913-588-6029
Fax+1 913-588-9822
Dr. Sharma is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2002 - 2005- University of Kansas School of MedicineChief Residency, Internal Medicine, 2001 - 2002
- University of Kansas School of MedicineResidency, Internal Medicine, 1999 - 2001
Baroda Medical CollegeClass of 1997
Certifications & Licensure
KS State Medical License 2001 - 2026
MO State Medical License 2021 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy Start of enrollment: 2009 Mar 01
- Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. Start of enrollment: 2009 May 01
- Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression Start of enrollment: 2009 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.Lorenzo Gerratana, Carolina Reduzzi, Yue Ren, Rinath Jeselsohn, Reshma L Mahtani
Clinical Cancer Research. 2025-11-03 - Analysis of the Radiosensitivity Index (RSI) in Paired Pre- and Post-Neoadjuvant Therapy Triple-Negative Breast Cancer.Shane R Stecklein, Roberto Salgado, Julia R White, Bruce F Kimler, Rachel Yoder
International Journal of Radiation Oncology, Biology, Physics. 2025-09-25 - 1 citationsMammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data.Adam M Brufsky, Kent F Hoskins, Henry J Conter, Pond Kelemen, Mehran Habibi
JNCI Cancer Spectrum. 2025-09-01
Journal Articles
- Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus DocetaxelAmanda Amin, Jamie Wagner, Qamar J Khan, Roy A Jensen, Joshua M Mammen, Priyanka Sharma, Jennifer R Klemp, Clinical Cancer Research
Press Mentions
RSClin Tool N+ Enhances Breast Cancer Risk EstimatesJanuary 23rd, 2025- Trial Data Helped Guide Treatment of Stage II-III Triple-Negative Breast CancerDecember 11th, 2024
- Summing It Up: Neoadjuvant Therapy in Triple-Negative DiseaseApril 6th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
